A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Trial Details

NCT ID

NCT05372354

Phase

PHASE1 / PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

• CC-92480
• Tazemetostat
• BMS-986158
• Trametinib
• Dexamethasone

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Baltimore, Maryland, United States|39.29038,-76.61219
• Boston, Massachusetts, United States|42.35843,-71.05977
• Hackensack, New Jersey, United States|40.88593,-74.04347
• New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

• Relapsed or refractory multiple myeloma (MM) and must:
• Have documented disease progression during or after their last myeloma therapy.
• For Part 1 Dose Finding: Be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit…
• Must have measurable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.